PR PANGARAN – Based on the published preliminary clinical trial results, oral medication experimental Merck for Covid-19, molnupiravir can reduce about 50 percent of the chances hospitalized.
Not only that, oral medication from Merck This can also reduce the risk death for patients Covid-19 who have a serious illness.
Merck and its partner Ridgeback Biotherapeutics plan to seek US emergency use authorization for the pill Covid-19 as soon as possible and to submit applications to regulatory bodies worldwide.
Also Read: Link to Watch Love Bonds Friday October 1, 2021: Aldebaran Ready to Arrest Iqbal, Irvan Visits Sofia’s Grave
Due to the positive results, the Phase 3 trial was terminated early on the recommendation of an outside monitor.
“This will change the dialogue around how to manage Covid-19, ”Robert Davis, CEO Merck, told Reuters quoted PikiranRakyat-Pangandaran.com.
If allowed, molnupiravir, which is designed to insert errors into the genetic code of the virus, will be the first oral antiviral drug for Covid-19.
Also Read: The Biggest Fear of Every Zodiac: Leo is afraid of being forgotten, Libra is afraid of making the wrong decision
Rivals including Pfizer and Swiss pharmaceutical Roche Holding AG are racing to develop easy-to-use antiviral pills for Covid-19 but so far, only antibody cocktails – which must be administered intravenously – are approved to treat patients Covid-19 who are not hospitalized.